https://doi.org/10.5812/numonthly.14296

No Association Between Cyclosporine Levels and Dyslipidemia?

authors:

avatar Guido Filler 1 , 2 , 3 , *

Department of Pathology and Laboratory Medicine, University of Western Ontario, Ontario, Canada
Department of Pediatrics, University of Western Ontario, Ontario, Canada
Department of Medicine, University of Western Ontario, Ontario, Canada
Nephro-Urology Monthly: Vol.6, issue 1; e14296
published online: January 13, 2014
article type: Letter
received: August 19, 2013
accepted: December 1, 2013

how to cite: Filler G. No Association Between Cyclosporine Levels and Dyslipidemia?. Nephro-Urol Mon. 2014;6(1):e14296. https://doi.org/10.5812/numonthly.14296.

Dear Editor,

The recent manuscript analyzing whether there was a correlation between cyclosporine levels and dyslipidemia after renal transplantation in 1391 kidney transplant recipients (1) was read with great interest. Dyslipidemia is a common problem after renal transplantation and a potentially modifiable factor (2). This is particularly important because cardiovascular morbidity significantly contributes to the below-average life expectancy found in renal transplant patients (3).

In their cross-sectional study of 1391 subjects, Hosseini et al. found a very high prevalence of hypercholesterolemia (58.8%) and hypertriglyceridemia (86.6%) (1). Using univariate correlation analysis, they found only a weak correlation between cyclosporine levels two hours post-intake (C2) and dyslipidemia (Pearson correlation coefficient 0.18 and 0.16 for hypercholesterolemia and hypertriglyceridemia, respectively). C2-monitoring is the preferred method for assessing cyclosporine exposure, although there are some challenges with timely C2 blood sampling, and some patients may suffer toxicity or rejection when switching from trough level (C0) to C2 monitoring (4). Using logistic multivariate regression, only serum creatinine was associated with hyperlipidemia. Hosseini’s study did not assess the correlation of steroid levels or the steroid dose and dyslipidemia, even though steroid therapy is a well-known risk factor for hyperlipidemia and steroid avoidance has been a powerful tool to reduce the prevalence of hyperlipidemia in liver transplantation (5).

Hosseini’s study has several other limitations. No validation of the fasting state occurred. The results of the logistic regression were not well documented, and it is unclear what factors were included in the multivariate analysis. The limitations of the cross-sectional retrospective study are not well discussed, and such a study can only assess an association, no causality. Nonetheless, the stronger correlation of the hypertriglyceridemia with the GFR (measured as serum creatinine) is interesting; it is disappointing that targeting optimal calcineurin inhibitor exposure has little effect on hyperlipidemia. The authors call for prospective trials targeting better lipid control, with the hope that long-term outcomes will improve.

The authors are correct in their assessment that chronic kidney disease (CKD)-related complications after renal transplantation are poorly managed (3, 6, 7). Often, there is undertreatment of dyslipidemia. Longevity after renal transplantation could be improved significantly if similar multidisciplinary clinics were introduced as for CKD in the primary kidneys (8). It is of the utmost importance to determine whether targeting conventional cardiovascular risk factors can effectively modify cardiovascular morbidity (9). In a large study of national data, Sciarretta et al. found no association of renal damage with cardiovascular disease and the individual cardiovascular risk profile (9). It is also important to determine which intervention is most effective and what novel therapies can be employed to lower triglycerides. There is no known effective treatment of hypertriglyceridemia. Dietary approaches such as supplementation with omega-3 fatty acids should be studied prospectively (10).

Nonetheless, the undersigned is delighted that the attention is shifting towards modifiable long-term complications after renal transplantation. Cardiovascular risk factors are among the most significant factors affecting long-term outcomes in renal transplant recipients and are responsible for deaths with functioning graft. CKD is a major risk factor for cardiovascular morbidity following transplantation, and has a high prevalence in both renal and non-renal transplant patients. The relationship between impaired GFR and dyslipidemia needs to be studied further and effective therapeutic interventions have to be found.

References

  • 1.

    Hosseini M, Rostami Z, Einollahi B. Dyslipidemia After Kidney Transplantation and Correlation With Cyclosporine Level. Nephr Urol Mon. 2013;5(3):831-4. https://doi.org/10.5812/numonthly.11890.

  • 2.

    Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Ame J Kidney Dis. 1998;32(5):853-906. [PubMed ID: 9820460].

  • 3.

    Filler G. Challenges in pediatric transplantation: the impact of chronic kidney disease and cardiovascular risk factors on long-term outcomes and recommended management strategies. Pediatr Transplant. 2011;15(1):25-31. [PubMed ID: 21155958]. https://doi.org/10.1111/j.1399-3046.2010.01439.x.

  • 4.

    Zhang Y, Zhang XD, Wang Y. Efficacy and safety of changing from cyclosporine C0 to C2 monitoring in stable recipients following renal transplantation: a prospective cohort study. Transplant Proc. 2011;43(10):3697-701. [PubMed ID: 22172829]. https://doi.org/10.1016/j.transproceed.2011.08.105.

  • 5.

    Segev DL, Sozio SM, Shin EJ, Nazarian SM, Nathan H, Thuluvath PJ, et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl. 2008;14(4):512-25. [PubMed ID: 18383081]. https://doi.org/10.1002/lt.21396.

  • 6.

    Feber J, Wong H, Geier P, Chaudry B, Filler G. Complications of chronic kidney disease in children post-renal transplantation - a single center experience. Pediatr Transplant. 2008;12(1):80-4. [PubMed ID: 18186892]. https://doi.org/10.1111/j.1399-3046.2007.00782.x.

  • 7.

    Akbari A, Hussain N, Karpinski J, Knoll GA. Chronic kidney disease management: comparison between renal transplant recipients and nontransplant patients with chronic kidney disease. Nephron Clin Pract. 2007;107(1):c7-13. [PubMed ID: 17622770]. https://doi.org/10.1159/000105138.

  • 8.

    Filler G, Lipshultz SE. Why multidisciplinary clinics should be the standard for treating chronic kidney disease. Pediatr Nephrol. 2012;27(10):1831-4. [PubMed ID: 22760413]. https://doi.org/10.1007/s00467-012-2236-3.

  • 9.

    Sciarretta S, Valenti V, Tocci G, Pontremoli R, Rosei EA, Ambrosioni E, et al. Association of renal damage with cardiovascular diseases is independent of individual cardiovascular risk profile in hypertension: data from the Italy - Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. J Hypertens. 2010;28(2):251-8. [PubMed ID: 19812502]. https://doi.org/10.1097/HJH.0b013e3283326718.

  • 10.

    Filler G, Weiglein G, Gharib MT, Casier S. Omega3 fatty acids may reduce hyperlipidemia in pediatric renal transplant recipients. Pediatr Transplant. 2012;16(8):835-9. [PubMed ID: 22835217]. https://doi.org/10.1111/j.1399-3046.2012.01772.x.